| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6509013 | GENZYME | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5496545 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7014846 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7459151 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5667775 | GENZYME | Phosphate-binding polymers for oral administration |
Sep, 2014
(9 years ago) | |
| US6733780 | GENZYME | Direct compression polymer tablet core |
Oct, 2020
(3 years ago) | |
Renagel is owned by Genzyme.
Renagel contains Sevelamer Hydrochloride.
Renagel has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Renagel are:
- US6509013
- US5496545
- US7014846
- US7459151
- US5667775
- US6733780
Renagel was authorised for market use on 12 July, 2000.
Renagel is available in tablet;oral, capsule;oral dosage forms.
Renagel can be used as phosphate binding.
The generics of Renagel are possible to be released after 18 October, 2020.
Drugs and Companies using SEVELAMER HYDROCHLORIDE ingredient
Market Authorisation Date: 12 July, 2000
Treatment: Phosphate binding
Dosage: TABLET;ORAL; CAPSULE;ORAL
How can I launch a generic of RENAGEL before it's drug patent expiration?
More Information on Dosage
RENAGEL family patents
